drugset / Trial / NCT07342283
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, prospective study enrolling 30 patients with stage II-III triple-negative breast cancer. The neoadjuvant regimen consists of QL1706 combined with carboplatin plus albumin-bound paclitaxel (21-day cycles for 4 cycles) followed by QL1706 combined with doxorubicin/epirubicin plus cyclophosphamide (21-day cycles for 4 cycles). The treatment observation period is 1 year, and the primary endpoint is the pathological complete response rate.
Timeline
- Start
- 2026-02-25
- Primary completion
- 2027-12-25
- Completion
- 2028-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | — |
| Background | Carboplatin | Small molecule | 2 unknown | — |
| Background | Carboplatin | Small molecule | 3 unknown | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Epirubicin | Small molecule | 90 mg/m2 | — |
| Background | Epirubicin | Small molecule | 100 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | — |